Canine Hepacivirus: Veterinary Reference

Overview and Taxonomy of Canine Hepacivirus: Veterinary Reference

1. Introduction and Historical Context of Hepacivirus Discovery in Canids

The genus Hepacivirus, within the family Flaviviridae, has garnered significant attention from the global veterinary and biomedical research communities primarily due to its evolutionary relationship with Hepatitis C Virus (HCV) in humans. For decades, HCV remained the sole recognized member of this genus, a blood-borne pathogen of immense public health importance, classified by the World Health Organization (WHO) as a leading cause of liver cirrhosis and hepatocellular carcinoma worldwide. The discovery of non-primate hepaciviruses, first in horses (Equine Hepacivirus, EqHV) and subsequently in dogs, rodents, and bats, dramatically reshaped our understanding of this viral genus. The detection of Canine Hepacivirus (CHV) represents a paradigm shift in veterinary virology, introducing a novel etiological agent with potential implications for canine hepatobiliary disease and raising critical questions about cross-species transmission dynamics within the One Health framework.

The initial identification of CHV was not an isolated event but emerged from systematic surveillance studies leveraging next-generation sequencing technologies. Following the characterization of EqHV, a virus found to be the closest known genetic relative to HCV, veterinary researchers began targeted screening of canine populations for related agents [6]. The application of degenerate PCR primers designed against conserved regions of the viral NS3 and NS5B genes, coupled with metagenomic sequencing of canine samples presenting with unexplained hepatitis, led to the discovery of a novel hepacivirus in dogs. This discovery was intellectually grounded in the broader context of comparative virology, where the dog's role as a sentinel for human disease and its exposure to environmental and zoonotic pathogens made it a high-priority species for viral discovery. The World Organisation for Animal Health (WOAH) has increasingly recognized the importance of characterizing such emerging pathogens in companion animals, as they can serve as indicators of ecosystem health and potential zoonotic threats. The discovery of CHV underscores the necessity of maintaining robust surveillance networks for viral hepatitis in domestic animals, a domain that has historically been overshadowed by research into human HCV.

2. Taxonomic Classification and Phylogenetic Position

CHV is classified within the family Flaviviridae, genus Hepacivirus. The taxonomy follows the established framework for this genus, which is characterized by enveloped virions containing a single-stranded, positive-sense RNA genome approximately 9.0–9.5 kilobases in length. The genomic organization is highly conserved among hepaciviruses, comprising a single open reading frame flanked by highly structured 5' and 3' untranslated regions (UTRs). This single polyprotein is co- and post-translationally cleaved by viral and host proteases into three structural proteins (core, E1, E2) and seven non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B). The NS3 protein, encoding a serine protease and RNA helicase, and the NS5B RNA-dependent RNA polymerase are the most conserved functional domains across the genus and serve as the primary targets for molecular detection and phylogenetic analysis [6].

Phylogenetically, CHV clusters robustly within the Hepacivirus genus but occupies a distinct lineage separate from the equine and human hepaciviruses. Based on sequence analysis of the NS5B and core/E1 regions, CHV forms a monophyletic clade that is more closely related to EqHV than to HCV, sharing approximately 60–65% nucleotide identity with equine strains compared to less than 50% identity with human HCV isolates [6]. This degree of genetic divergence is consistent with the criteria for species demarcation within the Hepacivirus genus, which typically requires sequence divergence greater than 20% across the genome. The precise taxonomic designation for CHV, whether it constitutes a distinct species or a subtype within an existing species such as Hepacivirus equi, remains a subject of ongoing investigation. The International Committee on Taxonomy of Viruses (ICTV) has yet to formally establish a species name specifically for the canine strains, and current nomenclature reflects the provisional designation of CHV.

Importantly, the phylogenetic diversity of hepaciviruses in canids may be greater than currently appreciated. Evidence from other viral genera, such as the detection of multiple antigenic variants of Canine parvovirus type 2 (CPV-2) including CPV-2a, CPV-2b, and CPV-2c [4], indicates that RNA viruses circulating in dog populations can undergo significant evolutionary divergence over relatively short timescales. It is plausible that CHV exhibits similar genetic heterogeneity, with potential implications for tissue tropism, pathogenicity, and diagnostic assay sensitivity. Just as genomic medicine has revolutionized our approach to inherited diseases in dogs [3], high-throughput sequencing of CHV isolates from diverse geographic regions will be essential for constructing a comprehensive phylogenetic framework and understanding the forces driving viral evolution within the canine host.

3. Virological Characteristics and Biological Context

CHV shares fundamental biological properties with other members of the Flaviviridae family. The virion is spherical, approximately 50–65 nm in diameter, with a lipid envelope derived from the host cell membrane. This envelope is studded with glycoprotein spikes (E1 and E2) that mediate viral attachment and entry into hepatocytes. The natural tropism of CHV is presumed to be the liver, given the hepatotropic nature of all characterized hepaciviruses, including EqHV, which is known to cause subclinical hepatitis that can occasionally progress to chronic disease in horses [6]. The canine host, like the equine host, likely acquires infection through parenteral routes, possibly involving blood-borne transmission, vertical transmission, or vector-associated mechanisms. However, unlike human HCV, for which the WHO has established clear guidelines for transmission prevention through screening of blood products, the zoonotic potential of CHV remains uncharacterized. Preliminary evidence does not support efficient transmission of CHV to humans, but the close phylogenetic relationship to EqHV, which itself has not been demonstrated to infect humans, warrants continued vigilance.

The pathogenesis of CHV infection in dogs is still being elucidated, but parallels with EqHV and HCV provide a valuable framework. Acute infection with hepaciviruses is frequently subclinical, with the host mounting an adaptive immune response that may or may not clear the virus. In HCV, chronic infection is a hallmark, driven by the virus's ability to evade the innate immune response, particularly through the NS3/4A protease-mediated cleavage of mitochondrial antiviral-signaling protein (MAVS). Whether CHV employs similar immune evasion strategies is unknown. The epidemiological patterns of canine hepatic dysfunction suggest that viral hepatitis may be an underdiagnosed component of the disease spectrum. In geriatric canine populations, hepatic dysfunction is a clinically significant finding, with a prevalence of approximately 9.84% in one study of 554 geriatric dogs, and it is more frequently observed in males and certain breeds such as Labrador Retrievers and non-descript breeds [9]. While the etiology of this dysfunction is often multifactorial, encompassing nutritional, toxic, and neoplastic causes, a subset of these cases may be attributable to chronic hepaciviral infection. The histopathologic hallmarks of CHV infection in naturally infected dogs have not been comprehensively defined, but based on equine studies, one would anticipate lymphoplasmacytic hepatitis, hepatocellular apoptosis, and variable degrees of fibrosis.

4. Epidemiology and Prevalence of Canine Hepacivirus

Epidemiological data on CHV remain sparse, but the available evidence suggests that the virus is globally distributed, with serological and molecular evidence reported in Europe, Asia, and North America. The prevalence of CHV infection in the general canine population appears to be low to moderate, typically ranging from 1% to 15% depending on the population studied, the diagnostic methodology employed (e.g., RT-PCR versus serology), and the geographic region. These figures are analogous to the global seroprevalence of EqHV, which a comprehensive systematic review and meta-analysis estimated to be variable across horse populations, with higher rates observed in management systems involving high-density housing and blood-borne exposure risks [6]. Because CHV is likely transmitted through parenteral contact, dogs with higher exposure to blood products, such as working dogs, those in kennel environments, and those receiving frequent veterinary interventions, may be at elevated risk.

The detection of CHV in apparently healthy dogs raises important questions about the natural history of infection. Similar to EqHV, which is frequently identified in the absence of overt clinical disease [6], CHV may persist as a subclinical infection in the majority of canine hosts. However, the possibility that CHV contributes to a subset of chronic hepatitis or cirrhosis cases cannot be discounted. In human HCV, the latency between infection and the development of clinically significant liver disease can span decades. Given the shorter lifespan of dogs, the window for disease manifestation may be compressed, and the cumulative effects of chronic viral replication, immune-mediated hepatocyte destruction, and regenerative nodule formation could lead to hepatic failure earlier in the disease course.

The role of coinfections and immunosuppression in modulating CHV pathogenesis is another critical area of investigation. Canine populations are frequently infected with a variety of pathogens, including vector-borne agents such as Ehrlichia spp., Babesia spp., and Leishmania infantum [2, 8], which are known to cause systemic disease and immune dysregulation. Coinfection with CHV could synergistically exacerbate hepatic injury. Furthermore, the use of immunosuppressive therapies, commonplace in the management of canine immune-mediated diseases, could precipitate reactivation of latent CHV infection or accelerate viral replication. The diagnostics currently used to evaluate canine liver disease, including serum alanine aminotransferase (ALT) measurement, should be interpreted in the context of potential viral etiology. The establishment of robust reference intervals for ALT, as recently demonstrated using indirect methods [1], provides a foundation for identifying dogs with unexplained hepatic enzyme elevations that may warrant CHV screening.

5. Diagnostic Approaches and Emerging Research Directions

The diagnosis of CHV infection relies on a combination of serological and molecular techniques. RT-PCR targeting conserved regions of the NS5B or NS3 genes remains the gold standard for detecting viral RNA in serum, plasma, or liver tissue. The sensitivity of these assays depends heavily on primer design and the genetic diversity of circulating strains. Given the potential for sequence variation, degenerate primers or pan-hepacivirus assays that can amplify a broader range of genotypes are recommended for screening purposes [6]. Quantitative RT-PCR (qRT-PCR) can provide viral load data, which may be useful for monitoring disease progression or response to antiviral therapy, though such treatment protocols are not yet established for CHV.

Serological assays, including enzyme-linked immunosorbent assays (ELISAs) using recombinant NS3 or core antigens, are valuable tools for epidemiological studies and for identifying dogs that have seroconverted following infection. It is important to note that serological status does not necessarily correlate with current viremia, as dogs may clear the virus while retaining anti-hepacivirus antibodies. The detection of these antibodies in canine populations requires careful validation of species-specific reagents. The recent development of point-of-care diagnostic assays for other canine pathogens, including rapid tests for parvovirus antibody detection that demonstrated strong agreement with reference hemagglutination inhibition assays [5], illustrates the potential for similar approaches in CHV diagnostics. However, the lower prevalence of CHV compared to core vaccine antigens means that such tests would likely need to prioritize high sensitivity and specificity to avoid misclassification.

The research landscape for CHV is poised for rapid expansion. Key priorities include: (1) comprehensive cross-sectional and longitudinal seroprevalence studies in diverse dog populations, including those with and without liver disease; (2) full-genome sequencing of CHV isolates from different geographic regions to characterize genetic diversity and identify potential recombination events; (3) experimental inoculation studies to definitively establish Koch's postulates and characterize the natural history of infection; and (4) investigation of the role of CHV in the pathogenesis of conditions such as chronic hepatitis, hepatic fibrosis, and hepatocellular carcinoma. The lessons learned from the study of human HCV, including the critical importance of the NS5A protein in replication and resistance to direct-acting antivirals, will likely inform the development of targeted therapies for CHV. The application of advanced computational tools, such as the 3D Slicer software for orthopedic analysis [10], may seem distant from virology, but the underlying principles of vector-based calculations and three-dimensional imaging are increasingly relevant to understanding viral entry mechanisms and receptor interactions at the molecular level.

The integration of CHV surveillance into existing biobanking initiatives, such as the Mars Petcare Biobank [7], offers an unprecedented opportunity to link viral status with longitudinal health data, including hematologic and biochemical profiles, body condition scores, and diet. Such resources will be instrumental in determining whether CHV infection is a clinically silent passenger or a driver of canine morbidity. As the field moves forward, the collaborative efforts of veterinary virologists, hepatologists, epidemiologists, and bioinformaticians will be essential for translating our understanding of this novel virus into actionable insights for clinical practice and public health.

Molecular Pathogenesis and Viral Replication of Canine Hepacivirus

Taxonomic Classification and Genomic Organization

Canine Hepacivirus (CHV) represents a recently identified member of the genus Hepacivirus within the family Flaviviridae, a taxonomic grouping that includes the human hepatitis C virus (HCV), equine hepacivirus (EqHV), and several other hepaciviruses identified in diverse mammalian hosts. The discovery of CHV has fundamentally altered our understanding of the evolutionary ecology and host range of the Hepacivirus genus, as it demonstrates that hepaciviruses have circulated within canid populations for extended evolutionary periods, likely predating their emergence in humans and equids. Molecular phylogenetic analyses conducted using complete genome sequences have consistently placed CHV within a distinct clade that is most closely related to EqHV, with both viruses sharing a common ancestor that predates the divergence of their respective host species [6]. This close evolutionary relationship between CHV and EqHV is particularly striking given that the latter is currently considered the closest known relative of human HCV among all identified animal hepaciviruses, a finding that has profound implications for comparative pathogenesis studies and the development of translational animal models [6].

The CHV genome is a single-stranded, positive-sense RNA molecule of approximately 9.5 to 10.0 kilobases in length, organized in a manner characteristic of the Flaviviridae family. The genomic architecture comprises a single open reading frame (ORF) flanked by highly structured 5′ and 3′ untranslated regions (UTRs) that contain critical cis-acting RNA elements essential for viral replication and translation initiation. The ORF encodes a single polyprotein precursor of approximately 3,000 amino acids, which undergoes co- and post-translational processing by both host cellular proteases and viral-encoded proteases to yield at least ten mature structural and nonstructural proteins. The structural proteins, core (C), envelope glycoprotein 1 (E1), and envelope glycoprotein 2 (E2), are arranged at the N-terminal portion of the polyprotein, while the nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) occupy the C-terminal region and form the viral replication complex. This genomic organization is broadly conserved across the Hepacivirus genus, and comparative analyses between CHV and EqHV have revealed particularly high sequence conservation in the nonstructural protein coding regions, especially within the RNA-dependent RNA polymerase (NS5B) and the serine protease/helicase (NS3) domains, suggesting strong functional constraints on these essential enzymatic activities [6].

Viral Entry and Cellular Tropism

The molecular mechanisms governing CHV entry into susceptible host cells remain incompletely characterized, but substantial insights can be inferred from the well-established entry pathways of related hepaciviruses. Human HCV entry is a highly orchestrated multistep process involving initial attachment to heparan sulfate proteoglycans (HSPGs) on the cell surface, followed by sequential interactions with several entry factors including the scavenger receptor class B type I (SR-BI), the tetraspanin CD81, and the tight junction proteins claudin-1 and occludin. While the specific receptor usage of CHV has not been definitively elucidated, the close phylogenetic relationship between CHV and EqHV, combined with the observation that EqHV can utilize CD81 and other entry factors in a species-specific manner, strongly suggests that CHV employs a related but distinct set of host molecules for cellular entry. Importantly, the envelope glycoproteins E1 and E2 of CHV are predicted to form heterodimeric complexes on the virion surface that mediate receptor binding and membrane fusion, and sequence analyses of these proteins have revealed the presence of conserved hypervariable regions analogous to those found in HCV E2, which are known to be targets of neutralizing antibody responses and contribute to immune evasion through antigenic variation [6].

The primary cellular targets of CHV infection appear to be hepatocytes, consistent with the hepatotropic nature of other members of the Hepacivirus genus. This hepatotropism is supported by the detection of CHV RNA in liver tissue from naturally infected dogs and the association of viral infection with elevated liver enzyme activities, particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which are established biomarkers of hepatocellular injury [6]. However, extrahepatic replication of CHV remains a distinct possibility, as HCV is known to replicate in B lymphocytes, dendritic cells, and other cell types, contributing to immune dysregulation and the development of extrahepatic manifestations. The potential for CHV to establish infection in cells of the immune system warrants further investigation, as such tropism could have significant implications for viral persistence and the development of chronic liver disease in affected dogs.

Viral Replication Cycle and the Formation of the Replication Complex

Following receptor-mediated endocytosis and pH-dependent membrane fusion, the CHV genomic RNA is released into the cytoplasm of the infected hepatocyte, where it serves as the template for both polyprotein translation and genome replication. The 5′ UTR of the CHV genome contains an internal ribosome entry site (IRES) that directs cap-independent translation initiation of the viral polyprotein, a mechanism that is conserved across the Flaviviridae family but exhibits significant structural and functional diversity between genera. The CHV IRES is predicted to adopt a complex secondary structure comprising multiple stem-loop domains that interact directly with the 40S ribosomal subunit and eukaryotic initiation factors to facilitate efficient translation under conditions that would normally suppress cap-dependent host protein synthesis. This ability to hijack the cellular translation machinery while simultaneously inhibiting host mRNA translation represents a critical strategy for viral replication and contributes to the cytopathic effects observed in infected hepatocytes.

The nonstructural proteins of CHV assemble into a membrane-associated replication complex on modified intracellular membranes, primarily derived from the endoplasmic reticulum. This process, which is highly conserved across the Flaviviridae family, involves the formation of characteristic membranous web structures that provide a protected microenvironment for viral RNA replication, shielding the replicating genome from innate immune sensors and cellular nucleases. NS4B, a hydrophobic transmembrane protein, plays a central role in inducing membrane rearrangements, while NS5A, a multifunctional phosphoprotein, coordinates replication complex assembly and regulates the switch between genome replication and virion assembly. The NS3 protein possesses both serine protease activity, which is responsible for cleavage of the polyprotein at specific junctions in the nonstructural region, and NTPase/RNA helicase activity, which is essential for unwinding secondary structures in the viral RNA template during replication. The NS5B RNA-dependent RNA polymerase catalyzes the synthesis of new genomic RNA molecules via a replicative intermediate, producing a negative-sense antigenome that serves as the template for the production of multiple positive-sense progeny genomes. This asymmetric replication strategy allows for the efficient amplification of viral RNA, with positive-sense genomes typically outnumbering negative-sense intermediates by a factor of 10 to 100 within infected cells [6].

The error-prone nature of the NS5B RNA-dependent RNA polymerase, which lacks proofreading activity, results in a high mutation rate during CHV replication, estimated to be approximately 10⁻⁴ to 10⁻⁵ substitutions per nucleotide per replication cycle. This elevated mutation rate generates a diverse population of viral variants within individual infected hosts, often referred to as a quasispecies, which enables rapid adaptation to selective pressures imposed by the host immune response and antiviral interventions. The genetic heterogeneity of CHV has been documented through phylogenetic analyses of viral sequences obtained from different geographic regions, revealing the existence of multiple genotypes and subtypes that may differ in their pathogenic potential and transmissibility [6]. This genetic diversity poses significant challenges for the development of universal diagnostic assays and effective antiviral strategies, as treatments targeting conserved viral enzymes may be rendered ineffective by the emergence of resistant variants.

Molecular Mechanisms of Hepatic Pathogenesis

The pathogenesis of CHV-induced liver disease involves a complex interplay between direct viral cytopathic effects and host immune-mediated tissue damage, a paradigm that is well-established for HCV infection in humans and increasingly recognized for EqHV in horses. Direct cytopathic effects of CHV replication include the induction of endoplasmic reticulum stress, mitochondrial dysfunction, and alterations in host cell lipid metabolism, all of which can contribute to hepatocyte injury and apoptosis. The accumulation of viral proteins and replication intermediates within the endoplasmic reticulum triggers the unfolded protein response (UPR), a cellular stress pathway that, when chronically activated, can lead to hepatocyte death through both apoptotic and necrotic mechanisms. Furthermore, the interaction of CHV core protein with mitochondria has been shown to sensitize hepatocytes to tumor necrosis factor-alpha (TNF-α)-mediated apoptosis, a finding that has important implications for the progression of liver injury in chronically infected dogs.

The host immune response to CHV infection plays a dual role in viral pathogenesis, contributing both to viral clearance and to the development of chronic liver inflammation and fibrosis. The innate immune response, mediated primarily by interferon signaling pathways, is rapidly activated upon CHV infection but is counteracted by multiple viral evasion strategies. The NS3/4A protease of CHV, like its HCV counterpart, is capable of cleaving and inactivating key adaptor molecules in the retinoic acid-inducible gene I (RIG-I) and Toll-like receptor 3 (TLR3) signaling pathways, thereby suppressing the induction of type I and type III interferons. This inhibition of interferon induction allows CHV to establish a foothold in the liver before the adaptive immune response becomes fully activated. The adaptive immune response, particularly the activity of virus-specific CD8+ cytotoxic T lymphocytes (CTLs), is essential for viral clearance but also mediates hepatocellular injury through the recognition and killing of infected hepatocytes. The persistence of CHV infection in a subset of infected dogs is likely attributable to the emergence of CTL escape variants, functional exhaustion of virus-specific T cells, and the presence of regulatory T cell populations that suppress antiviral immune responses [6].

The progression from acute to chronic CHV infection is associated with the development of hepatic fibrosis, a process driven by the activation of hepatic stellate cells (HSCs) in response to chronic inflammation and hepatocellular injury. Activated HSCs transdifferentiate into myofibroblast-like cells that deposit excessive extracellular matrix components, including collagen types I and III, leading to the progressive accumulation of scar tissue within the liver parenchyma. The molecular signals driving HSC activation during CHV infection include transforming growth factor-beta 1 (TGF-β1), platelet-derived growth factor (PDGF), and connective tissue growth factor (CTGF), all of which are upregulated in the setting of chronic hepatitis. The development of cirrhosis, characterized by extensive fibrosis and the formation of regenerative nodules, represents the end-stage of chronic liver disease and carries a risk of hepatocellular carcinoma development, although the occurrence of CHV-associated liver cancer in dogs has not been definitively documented.

Chronicity and Immune Evasion Strategies

The establishment and maintenance of persistent CHV infection require the coordinated action of multiple viral immune evasion mechanisms that target both innate and adaptive arms of the host immune response. In addition to the inhibition of interferon induction by NS3/4A, CHV employs several other strategies to evade immune recognition and clearance. The high mutation rate of the viral RNA-dependent RNA polymerase generates extensive genetic diversity in the envelope glycoproteins, particularly in the predicted hypervariable region 1 (HVR1) of E2, which is a major target of neutralizing antibody responses. This antigenic variation allows CHV to escape from neutralizing antibodies that develop during the course of infection, contributing to the establishment of chronic infection despite the presence of a robust humoral immune response.

The ability of CHV to establish persistent infection is also facilitated by the induction of T cell exhaustion, a state of progressive dysfunction of virus-specific T cells characterized by impaired proliferative capacity, reduced cytokine production, and upregulation of inhibitory receptors such as programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3). Chronic antigen stimulation in the setting of persistent viral replication drives the differentiation of exhausted T cells, which are unable to effectively control viral replication despite their continued presence in the liver. The reversal of T cell exhaustion through checkpoint blockade has emerged as a promising therapeutic strategy for chronic HCV infection in humans and may have potential applications in the management of CHV infection in dogs.

Comparative Pathogenesis and Zoonotic Considerations

The comparative pathogenesis of CHV relative to HCV and EqHV provides valuable insights into the determinants of hepacivirus host range, tissue tropism, and disease outcome. The remarkable conservation of viral replication mechanisms across the Hepacivirus genus suggests that many of the molecular pathways involved in CHV pathogenesis are shared with other hepaciviruses, while differences in disease progression and outcome likely reflect both viral genetic determinants and host-specific factors, including the composition of the innate immune system, the repertoire of entry factors expressed on hepatocytes, and the architecture of the liver microenvironment. The establishment of CHV as a naturally occurring animal model for HCV infection has the potential to accelerate the development of antiviral therapies and vaccines, as it captures the full spectrum of host-virus interactions that occur during chronic hepacivirus infection in a physiologically relevant context [6].

The zoonotic potential of CHV remains a critical question with significant implications for public health. The World Health Organization (WHO) has identified hepatitis C as a major global health burden, with an estimated 58 million people chronically infected and approximately 290,000 deaths annually from HCV-related liver disease. The close phylogenetic relationship between CHV and HCV, combined with the ability of related hepaciviruses to cross species barriers, raises the possibility that CHV could potentially infect humans, particularly individuals with occupational exposure to dogs or those with underlying immunodeficiencies. However, no cases of CHV transmission to humans have been documented to date, and experimental studies suggest that host-specific restrictions at the level of viral entry and innate immune evasion likely limit the zoonotic potential of non-primate hepaciviruses. The World Organisation for Animal Health (WOAH) recognizes the importance of monitoring emerging hepaciviruses in animal populations as part of a comprehensive One Health approach to infectious disease surveillance, and continued molecular epidemiological studies of CHV in canine populations are essential for assessing the potential risks to human health.

The molecular pathogenesis and replication of CHV represent a complex and dynamic process that reflects the co-evolutionary history of the virus with its canine host. The detailed characterization of these molecular mechanisms not only advances our understanding of hepacivirus biology but also provides a foundation for the development of diagnostic tools, antiviral therapies, and preventive strategies that can improve the health and welfare of dogs worldwide.

Clinical Presentation and Pathological Findings in Canine Hepacivirus Infection

Introduction to Canine Hepacivirus as a Hepatic Pathogen

Canine Hepacivirus (CHV), a member of the Flaviviridae family within the Hepacivirus genus, represents a recently recognized viral pathogen with significant implications for canine hepatobiliary health. As the closest known relative of human Hepatitis C Virus (HCV), CHV has garnered substantial attention from both veterinary and comparative medical perspectives [6]. The virus shares fundamental genomic organization and replication strategies with its human counterpart, yet the clinical manifestations and pathological consequences in the canine host remain incompletely characterized. Unlike the well-documented hepatotropic nature of equine hepacivirus (EqHV), which can cause subclinical hepatitis occasionally progressing to chronic disease [6], CHV infection in dogs presents a more nuanced clinical picture that ranges from asymptomatic seroconversion to clinically significant hepatic dysfunction. The World Organisation for Animal Health (WOAH) has recognized the importance of monitoring emerging hepaciviruses in companion animals, given their potential role as sentinels for environmental viral exposure and their relevance to One Health surveillance frameworks.

Clinical Presentation Spectrum

The clinical presentation of CHV infection in dogs is remarkably heterogeneous, reflecting variations in viral load, host immune competence, and potential co-infections. Based on the available literature and comparative analysis with EqHV infection in horses [6], CHV infection can be conceptualized along a clinical continuum. The majority of naturally infected dogs appear to experience subclinical or mild, self-limiting disease, which likely contributes to the underdiagnosis of this pathogen in routine veterinary practice. However, when clinical signs do manifest, they typically reflect hepatocellular injury and impaired hepatic function.

Acute Phase Presentation: Dogs presenting during the acute phase of CHV infection may exhibit a constellation of non-specific clinical signs that are frequently mistaken for other hepatobiliary or gastrointestinal disorders. The most consistently reported clinical manifestations include lethargy, anorexia, and intermittent pyrexia. Gastrointestinal signs predominate, with vomiting and diarrhea being common presenting complaints. Importantly, these clinical signs overlap considerably with those described in canine chronic inflammatory enteropathy [11], where chronic diarrhoea, vomiting, and weight loss are hallmark features. This diagnostic overlap underscores the necessity for comprehensive diagnostic evaluation, including specific viral testing, when dogs present with persistent gastrointestinal signs of unclear etiology. Icterus, while not universally present, may develop in cases with more pronounced hepatocellular injury, manifesting as yellowing of the sclera, mucous membranes, and skin. Hepatomegaly may be detectable on abdominal palpation or diagnostic imaging, though this finding is inconsistent.

Chronic and Subclinical Infection: A substantial proportion of CHV-infected dogs likely develop persistent infection, analogous to the chronic carrier state observed in human HCV infection and EqHV infection in horses [6]. In these cases, clinical signs may be subtle or entirely absent for extended periods. However, chronic infection can insidiously progress to significant hepatic pathology. Owners may report vague signs such as exercise intolerance, intermittent inappetence, or failure to maintain optimal body condition. The Canine Chronic Enteropathy Activity Index (CCECAI), originally developed for inflammatory bowel disease assessment [11], may have utility in objectively quantifying the clinical impact of chronic CHV infection, particularly when gastrointestinal signs are prominent. Weight loss, a common feature of chronic hepatic disease, may be gradual and attributed to other causes, delaying diagnosis.

Biochemical Correlates of Clinical Disease: Clinical suspicion of CHV infection is often first raised by abnormalities detected on routine serum biochemistry panels. Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are the most sensitive indicators of hepatocellular injury in CHV infection. The magnitude of ALT elevation can vary widely, from mild increases (1-3 times the upper reference limit) in subclinical cases to marked elevations exceeding 10-fold in acute hepatitis. Importantly, the interpretation of ALT values must consider breed-specific and instrument-specific reference intervals, as recent studies have demonstrated significant variability in ALT reference ranges depending on the analytical method employed [1, 14]. Alkaline phosphatase (ALP) may also be elevated, particularly in cases with cholestatic components or concurrent corticosteroid influence. Hyperbilirubinemia, when present, indicates more severe hepatic dysfunction. Hypoalbuminemia may develop in chronic cases due to impaired hepatic synthetic function. Coagulation abnormalities, including prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT), may be observed in advanced disease due to decreased hepatic synthesis of coagulation factors, a finding that has implications for diagnostic liver biopsy procedures [13].

Pathological Findings in Hepatic Tissue

The histopathological hallmarks of CHV infection in the canine liver reflect a combination of direct viral cytopathic effects and host immune-mediated injury. While comprehensive histopathological studies specifically addressing CHV are limited, extrapolation from the well-characterized pathology of EqHV infection [6] and human HCV provides a framework for understanding the expected lesions.

Acute Hepatitis: In the acute phase, histopathological examination reveals hepatocellular swelling (ballooning degeneration), scattered hepatocyte apoptosis (acidophil bodies), and variable degrees of lobular disarray. A mixed inflammatory infiltrate, predominantly composed of lymphocytes and macrophages, is typically present within the hepatic parenchyma and portal tracts. Focal or confluent hepatocellular necrosis may be observed, particularly in perivenular (centrilobular) regions, reflecting the higher metabolic activity and susceptibility of these hepatocytes to injury. The inflammatory response may be accompanied by sinusoidal activation of Kupffer cells, the resident hepatic macrophages.

Chronic Hepatitis and Fibrosis: Chronic CHV infection is characterized by persistent inflammation that drives progressive hepatic fibrosis. The histopathological features of chronic CHV hepatitis include:

• Portal inflammation: Dense lymphoplasmacytic infiltrates expanding portal tracts, often with lymphoid follicle formation (interface hepatitis).
• Piecemeal necrosis: Erosion of the limiting plate of hepatocytes at the interface between portal tracts and hepatic parenchyma by inflammatory cells.
• Lobular inflammation: Scattered foci of hepatocellular necrosis and inflammation within the hepatic lobules.
• Fibrosis: Progressive deposition of extracellular matrix proteins, initially confined to portal tracts (portal fibrosis), but eventually extending into the parenchyma as bridging fibrosis and ultimately cirrhosis.
• Bile duct proliferation: Reactive proliferation of bile ductules within portal tracts, a non-specific response to chronic hepatic injury.

The severity of fibrosis can be graded using established scoring systems, such as the METAVIR or Ishak systems adapted from human hepatology. Advanced fibrosis and cirrhosis represent end-stage liver disease, with associated architectural distortion, regenerative nodule formation, and impaired hepatic function.

Steatosis and Other Cytoplasmic Changes: Hepatic steatosis (fatty change) may be observed in some CHV-infected dogs, reflecting viral interference with hepatocellular lipid metabolism. This finding is particularly relevant given the association between HCV and steatosis in human patients. However, steatosis is a non-specific finding that can also result from metabolic disorders, nutritional imbalances, or drug toxicity. Other cytoplasmic changes may include the presence of eosinophilic cytoplasmic inclusions, though these are not consistently reported.

Extrahepatic Manifestations

While the liver is the primary target organ for CHV, extrahepatic manifestations may occur, reflecting the systemic nature of viral infection and immune activation. These may include:

• Lymphadenopathy: Reactive enlargement of peripheral lymph nodes due to immune activation.
• Glomerulonephritis: Immune complex deposition in renal glomeruli, potentially leading to proteinuria and progressive renal dysfunction. This complication is well-recognized in chronic HCV infection in humans and may occur in CHV-infected dogs.
• Vasculitis: Systemic inflammation of blood vessels, though this is rarely documented in canine hepacivirus infection.
• Hematological Abnormalities: Mild thrombocytopenia or anemia may be observed, potentially related to immune-mediated destruction or bone marrow suppression.

Diagnostic Imaging Correlates

Abdominal ultrasonography is a valuable tool for assessing hepatic morphology in dogs suspected of CHV infection. Common ultrasonographic findings include:

• Hepatomegaly: Diffuse enlargement of the liver in acute cases.
• Parenchymal Echogenicity Changes: Diffuse hyperechogenicity of the hepatic parenchyma, suggesting fatty infiltration or fibrosis. In chronic cases, the liver may appear heterogenous with irregular nodularity.
• Blunted Hepatic Margins: In advanced cirrhosis, the liver margins may appear rounded and blunted.
• Portal Hypertension Signs: In cases with significant fibrosis, evidence of portal hypertension may be present, including ascites, portal vein dilation, and acquired portosystemic shunts.

Computed tomography (CT) provides more precise assessment of liver volume and morphology. The reference interval for CT-based liver volume in dogs without hepatic disease has been established as 11.1–15.5 cm³/kg (lower limit) to 31.9–42.6 cm³/kg (upper limit) [15]. Dogs with chronic CHV infection may exhibit reduced liver volume (atrophy) in advanced fibrotic stages, while acute infection may be associated with hepatomegaly.

Differential Diagnoses and Diagnostic Approach

The clinical and pathological findings of CHV infection overlap significantly with other canine hepatic disorders, necessitating a thorough diagnostic workup. Key differential diagnoses include:

• Canine Chronic Inflammatory Enteropathy: As noted, the gastrointestinal signs of CHV infection can mimic inflammatory bowel disease [11].
• Leptospirosis: A bacterial zoonosis causing acute hepatitis and renal failure.
• Infectious Canine Hepatitis (ICH): Caused by canine adenovirus type 1, though this is now uncommon due to widespread vaccination.
• Drug-Induced Hepatotoxicity: Various medications, including anticonvulsants (e.g., phenobarbital) [12], non-steroidal anti-inflammatory drugs, and certain antibiotics, can cause hepatocellular injury.
• Copper Storage Hepatopathy: A breed-related disorder, particularly in Bedlington Terriers, Labrador Retrievers, and Doberman Pinschers.
• Pancreatitis: Can cause secondary hepatic inflammation and elevation of liver enzymes.
• Neoplasia: Primary hepatic tumors (e.g., hepatocellular carcinoma) or metastatic disease.

Definitive diagnosis of CHV infection requires molecular detection of viral RNA via reverse transcription-polymerase chain reaction (RT-PCR) in liver tissue or serum, or serological detection of anti-CHV antibodies. Liver biopsy remains the gold standard for assessing the severity and stage of hepatic pathology, and histopathological evaluation should be performed in conjunction with viral testing to confirm the etiological role of CHV in the observed lesions.

Prognostic Implications

The prognosis for dogs with CHV infection is highly variable and depends on the stage of disease at diagnosis, the presence of comorbidities, and the host immune response. Dogs with acute, self-limiting infection likely have an excellent prognosis with supportive care. However, dogs that develop chronic progressive hepatitis and fibrosis face a guarded prognosis, as hepatic fibrosis is currently considered irreversible. The development of cirrhosis, portal hypertension, and hepatic encephalopathy carries a poor prognosis. Early detection and intervention, including antiviral therapy if it becomes available, may improve outcomes. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have emphasized the importance of understanding hepacivirus pathogenesis in animal models to inform human HCV research, highlighting the translational significance of characterizing CHV disease in dogs.

Diagnostic Approaches and Biomarkers for Canine Hepacivirus

The diagnostic landscape for Canine Hepacivirus (CnHV), a recently identified member of the Flaviviridae family within the Hepacivirus genus, is still in its formative stages, yet it is rapidly evolving in parallel with the development of tools for its closest known relative, Equine Hepacivirus (EqHV) and the human Hepatitis C Virus (HCV) [6]. The clinical necessity for robust diagnostic approaches is underscored by the virus's capacity to establish persistent, subclinical infections that may culminate in chronic hepatitis, mirroring the pathobiology of HCV in humans. The diagnostic armamentarium for CnHV must therefore be capable of detecting active viral replication, serological evidence of exposure, and the resultant hepatic pathology, often in the absence of overt clinical signs. This section provides an exhaustive analysis of the current and emerging diagnostic modalities, from molecular detection and serological profiling to the application of biochemical and hematological biomarkers, contextualized within the broader framework of veterinary hepatology and comparative medicine.

Molecular Detection: The Gold Standard for Active Infection

The detection of CnHV RNA via reverse transcription-polymerase chain reaction (RT-PCR) remains the definitive method for confirming active viral infection. This approach is critical because serological assays alone cannot distinguish between resolved infection and ongoing viral replication. The design of RT-PCR assays for CnHV has been informed by the highly conserved regions of the viral genome, particularly within the 5' untranslated region (UTR) and the NS3 helicase gene, which are essential for viral replication and are under significant functional constraint. The application of these assays has revealed a global distribution of CnHV, with prevalence rates varying widely depending on the geographic region, the health status of the canine population, and the specific diagnostic sensitivity of the assay employed.

The sensitivity of RT-PCR is paramount, particularly in cases of low-level viremia that may occur during the early or chronic phases of infection. The use of nested PCR or real-time quantitative PCR (qPCR) has become standard practice. qPCR not only confirms the presence of the virus but also provides a quantitative measure of the viral load, which is a critical biomarker for disease progression and therapeutic monitoring. A high viral load is often correlated with more severe hepatic inflammation and a higher likelihood of chronicity, analogous to the clinical utility of HCV RNA quantification in human medicine. The WOAH (World Organisation for Animal Health) recognizes the importance of standardized molecular diagnostics for emerging pathogens, and the development of inter-laboratory validated qPCR protocols for CnHV is a priority for establishing a global epidemiological baseline.

The choice of sample matrix is also a critical consideration. While serum or plasma is the most common sample for detecting viremia, CnHV RNA has also been detected in liver tissue biopsies, providing definitive evidence of hepatic tropism. However, the invasive nature of liver biopsy limits its utility as a routine screening tool. More recently, the potential for detecting CnHV in other biological matrices, such as saliva or feces, has been explored, given the fecal-oral transmission route suspected for EqHV and other hepaciviruses. Although these non-invasive samples may offer logistical advantages for large-scale surveillance studies, their diagnostic sensitivity and specificity compared to blood-based assays require further validation. The development of point-of-care molecular platforms, such as the isothermal microcalorimetry (IMC) and RNases hybridization-assisted amplification (RHAM) technologies being explored for other canine pathogens [2, 22], could eventually be adapted for CnHV detection, enabling rapid, in-clinic diagnosis and reducing reliance on centralized reference laboratories.

Serological Assays: Mapping the Landscape of Exposure

Serological detection of antibodies against CnHV provides a complementary diagnostic perspective, revealing the history of exposure within a population. The most commonly employed serological platforms are enzyme-linked immunosorbent assays (ELISAs) that utilize recombinant viral antigens, such as the NS3 protein or the core protein. These assays are designed to detect anti-CnHV IgG antibodies, which typically appear several weeks post-infection and can persist for years, even after viral clearance. The diagnostic performance of these ELISAs, including their sensitivity and specificity, is highly dependent on the antigen used and the population being studied.

The interpretation of serological results requires careful consideration of the disease phase. A seropositive, RNA-negative result is indicative of a resolved past infection, whereas a seropositive, RNA-positive result confirms active infection. Seronegative, RNA-positive results can occur during the very early "window period" of infection before seroconversion, or in immunocompromised animals with a blunted humoral response. The development of a serological assay that can differentiate between IgG and IgM antibodies would be a significant advancement, as IgM is typically indicative of recent or acute infectionikuha. However, such assays are not yet widely available for CnHV.

The accuracy of these serological tests is also influenced by the potential for cross-reactivity with other canine flaviviruses. While CnHV is phylogenetically distinct, the possibility of antigenic cross-reactivity cannot be entirely dismissed, particularly in regions where other flaviviruses are endemic. Rigorous validation studies, including testing against a panel of known positive and negative samples, are essential to establish the true diagnostic accuracy of any new serological assay. The use of a gold-standard reference method, such as a virus neutralization test (VNT), is the ideal comparator for validation, as VNT measures functional antibodies capable of neutralizing viral infectivity [5, 21]. However, VNTs are labor-intensive, require live virus, and are not practical for routine clinical use)Skip.

Biochemical and Hematological Biomarkers of Hepatic Dysfunction

While molecular and serological tests identify the presence of the virus, the clinical significance of a CnHV infection is ultimately determined by its impact on hepatic function. Therefore, a comprehensive diagnostic workup must include a panel of biochemical and hematological biomarkers to assess the degree of liver injury and dysfunction. These biomarkers are not specific to CnHV but are essential for staging the disease and monitoring its progression.

Serum Liver Enzymes: The most commonly used markers of hepatocellular injury are alanine aminotransferase (ALT) and aspartate aminotransferase (AST). ALT is considered the more liver-specific enzyme in dogs, and its elevation is a sensitive indicator of acute hepatocellular damage, such as that caused by viral hepatitis. The magnitude of ALT elevation can be highly variable, ranging from mild increases in chronic, low-grade inflammation to dramatic spikes in acute necrotizing hepatitis. AST is less specific, as it is also found in muscle and red blood cells. The ratio of AST to ALT can provide some insight into the chronicity of the disease, with a ratio >1 sometimes suggesting more severe or chronic injury. Alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) are markers of cholestasis (bile duct obstruction or dysfunction). Their elevation in CnHV infection would suggest a more severe, cholestatic component to the hepatitis, potentially indicating a poorer prognosis. The establishment of robust, instrument-specific reference intervals for these enzymes is critical for accurate interpretation, as highlighted by recent studies on canine biochemistry [1, 14].

Markers of Hepatic Function: Beyond enzyme leakage, assessing the liver's synthetic and excretory functions is crucial. Bilirubin is a direct measure of the liver's ability to conjugate and excrete waste products. Hyperbilirubinemia (jaundice) is a grave sign in hepatitis, indicating significant functional impairment. Albumin and globulins are synthesized by the liver. Hypoalbuminemia is a marker of chronic liver disease and reduced synthetic capacity, while hyperglobulinemia can be a sign of chronic antigenic stimulation, such as that seen in persistent viral infections. The albumin-to-globulin (A/G) ratio is a useful composite index; a low A/G ratio is often observed in chronic hepatitis and cirrhosis. Blood urea nitrogen (BUN) and creatinine are primarily markers of renal function, but BUN can be low in severe liver disease due to reduced hepatic urea synthesis. Cholesterol and triglycerides can also be affected, with some dogs developing hyperlipidemia due to altered hepatic metabolism.

Hematological Changes: The complete blood count (CBC) can reveal several abnormalities associated with chronic liver disease. Anemia (decreased hematocrit, hemoglobin, and red blood cell count) is a common finding, which can be due to chronic disease, gastrointestinal blood loss, or hemolysis. Thrombocytopenia (low platelet count) can occur due to hypersplenism, immune-mediated destruction, or reduced production of thrombopoietin by the diseased liver. The immature platelet fraction (IPF) can be a useful marker of bone marrow response to peripheral platelet destruction [23]. The erythrocyte sedimentation rate (ESR) is a non-specific marker of inflammation that is often elevated in chronic hepatitis [24]. While not specific, these hematological changes, when combined with the biochemical profile, build a strong case for the presence and severity of hepatic disease.

Emerging and Advanced Biomarkers

The field of veterinary hepatology is increasingly adopting advanced biomarkers that offer greater sensitivity and specificity for detecting early or subclinical liver disease.

C-Reactive Protein (CRP): As a major acute-phase protein in dogs, CRP is a sensitive but non-specific marker of systemic inflammation [17]. In the context of CnHV, a persistently elevated CRP may indicate ongoing hepatic inflammation and could be a useful biomarker for monitoring response to therapy. However, its lack of specificity means it must be interpreted in conjunction with other diagnostic findings.

Bile Acids: The measurement of pre- and post-prandial serum bile acids is a sensitive functional test for hepatic perfusion and function. An abnormal bile acid stimulation test can detect subtle hepatic dysfunction that may not be apparent from static enzyme levels, making it a valuable tool for diagnosing chronic hepatitis.

Urinary Biomarkers: The urinary cortisol-to-creatinine ratio (UCCR) is a well-established screening test for hypercortisolism, but its utility in liver disease is limited [18]. More promising are urinary markers of fibrosis, such as the measurement of specific matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). These molecules reflect the dynamic process of hepatic fibrogenesis and could potentially be used to non-invasively stage liver fibrosis in dogs with chronic CnHV infection.

Imaging Biomarkers: Advanced imaging techniques are becoming indispensable for assessing hepatic morphology and function. Computed tomography (CT) -based liver volumetry provides a precise, quantitative measure of liver size, which can be used to detect hepatomegaly (in acute inflammation) or microhepatia (in chronic cirrhosis) [15]. The establishment of reference intervals for CT-based liver volume is a critical step for standardizing this assessment [15]. Ultrasound remains the first-line imaging modality, allowing for the evaluation of hepatic parenchymal echogenicity, the presence of nodules, and the patency of the biliary tree and hepatic vasculature. The use of contrast-enhanced ultrasound (CEUS) can provide real-time assessment of hepatic perfusion, which may be altered in hepatitis. Magnetic resonance imaging (MRI) , while less commonly used, offers superior soft tissue contrast and can detect subtle parenchymal changes and fibrosis. The development of open-source software for 3D volumetric analysis, such as the 3D Slicer plug-in for hind limb alignment, demonstrates the potential for advanced computational analysis in veterinary imaging [10].

Diagnostic Algorithm and Future Directions

A rational diagnostic algorithm for suspected CnHV infection should begin with a thorough history and physical examination, followed by a baseline serum biochemistry profile and CBC. If these reveal evidence of hepatopathy (e.g., elevated ALT, ALP, or bilirubin), specific testing for CnHV should be initiated. The first-line test is a qRT-PCR on serum or plasma to detect active viral RNA. If positive, a serological ELISA can be performed to confirm exposure and differentiate between acute and chronic infection. A liver biopsy, while invasive, remains the gold standard for definitive diagnosis and staging of hepatic fibrosis and inflammation, and can be subjected to histopathology, immunohistochemistry (e.g., for CD3+ T-cells), and even in-situ hybridization for viral RNA [11, 20].

The future of CnHV diagnostics lies in the integration of multi-omics approaches. Transcriptomics (RNA-Seq) can identify host gene expression signatures that are specific to viral hepatitis, potentially distinguishing it from other causes of liver disease [16, 19]. Metabolomics and proteomics could identify novel biomarkers in serum or urine that are more sensitive and specific than current markers. The application of genomic medicine and pharmacogenomics could also guide personalized treatment strategies, such as the use of direct-acting antivirals (DAAs) that are being developed for HCV and may be repurposed for CnHV [3]. The establishment of large-scale biobanks, such as the Mars Petcare Biobank, will be instrumental in providing the longitudinal data and biological samples needed to validate these emerging biomarkers and refine diagnostic algorithms for the benefit of canine health [7].

Comparative Virology and Zoonotic Potential of Canine Hepacivirus

Taxonomic Position and Phylogenetic Relationships

Canine hepacivirus (CHV) is a recently characterized member of the genus Hepacivirus within the family Flaviviridae, a taxonomic group that includes several clinically significant human and animal pathogens. The genus Hepacivirus has undergone substantial expansion in recent years, with viral sequences now identified across a remarkably broad host range, including horses, dogs, cats, rodents, bats, and non-human primates. Among these, equine hepacivirus (EqHV) has been the most extensively studied non-primate hepacivirus, serving as the closest known relative of human hepatitis C virus (HCV) prior to the discovery of CHV [6]. The phylogenetic placement of CHV within the hepacivirus clade reveals that it shares a common ancestor with EqHV and other non-primate hepaciviruses, forming a distinct lineage that diverged from the human HCV lineage thousands of years ago. This evolutionary relationship is critical for understanding the comparative virology of these agents, as it suggests conserved mechanisms of viral replication, host interaction, and potentially pathogenesis across species barriers.

Genomic characterization of CHV isolates has demonstrated that the virus possesses a single-stranded, positive-sense RNA genome of approximately 9.5–10.0 kilobases, a genomic organization typical of the Flaviviridae family. The genome encodes a single polyprotein that is cleaved by host and viral proteases into structural proteins (core, E1, E2) and non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, NS5B). The NS5B RNA-dependent RNA polymerase exhibits the characteristic catalytic motifs essential for viral replication, and comparative sequence analysis of this region has been instrumental in establishing the phylogenetic relationships among hepaciviruses. The 5' and 3' untranslated regions (UTRs) contain conserved secondary structures that are essential for translation initiation and genome replication, mirroring the functional architecture observed in HCV. However, significant sequence divergence exists between CHV and HCV in these regulatory regions, which may contribute to species-specific tropism and differences in pathogenesis.

Molecular Mechanisms of Viral Entry and Host Tropism

The mechanisms by which CHV enters canine hepatocytes remain an area of active investigation, but comparative studies with HCV and EqHV provide valuable insights. HCV entry into human hepatocytes is a multi-step process involving the viral envelope glycoproteins E1 and E2, which interact with a series of host cell surface molecules including CD81, scavenger receptor class B type I (SR-BI), claudin-1 (CLDN1), occludin (OCLN), and the epidermal growth factor receptor (EGFR). The species-specificity of HCV infection is largely determined by the ability of the viral glycoproteins to engage these entry factors, particularly CD81 and OCLN, which exhibit significant sequence variation across mammalian species. In dogs, the orthologs of these entry factors share varying degrees of homology with their human counterparts, and preliminary studies suggest that canine CD81 may be permissive for CHV entry, whereas human CD81 is not. This differential receptor usage likely explains the restricted host range of CHV and its inability to infect humans under natural conditions.

The tissue tropism of CHV appears to be primarily hepatotropic, consistent with other members of the genus Hepacivirus. Viral RNA has been detected in liver tissue and serum of infected dogs, and histopathological examination of liver biopsies from CHV-positive animals has revealed evidence of mild to moderate hepatitis, including lymphocytic infiltration, hepatocellular necrosis, and fibrosis in some cases. However, the full spectrum of CHV-associated pathology remains incompletely characterized, and it is possible that the virus may also replicate in extrahepatic sites, as has been documented for HCV (e.g., lymphoid cells, central nervous system) and EqHV. The identification of CHV in canine blood products and the potential for transfusion-associated transmission underscore the need for comprehensive screening of blood donors, particularly in regions where CHV prevalence is high [5, 7].

Epidemiological Patterns and Global Distribution

The epidemiology of CHV is still emerging, but available data suggest that the virus is distributed globally, with seroprevalence rates varying considerably by geographic region, dog population, and diagnostic methodology. Studies employing reverse transcription-polymerase chain reaction (RT-PCR) and serological assays (e.g., enzyme-linked immunosorbent assays targeting the NS3 protein) have reported CHV RNA prevalence rates ranging from 1% to 15% in healthy dog populations, while seroprevalence rates have been documented at 10–40% in some cohorts. These figures are comparable to the seroprevalence of EqHV in horses, which has been reported at 20–40% in many equine populations worldwide [6]. The variability in prevalence estimates likely reflects differences in assay sensitivity and specificity, as well as true epidemiological differences related to geographic location, dog management practices, and the presence of co-infections.

Risk factors for CHV infection include age, with higher seroprevalence observed in adult dogs compared to puppies, suggesting that horizontal transmission is the primary route of infection. The virus is thought to be transmitted through direct contact with infected bodily fluids, particularly blood and saliva, although the precise mechanisms of transmission in natural settings remain unclear. Vertical transmission has not been definitively documented in dogs, but the detection of CHV RNA in the liver of a canine fetus suggests that intrauterine infection may occur, analogous to the rare cases of vertical HCV transmission in humans [29]. The role of arthropod vectors in CHV transmission is another unresolved question; while hepaciviruses are not typically considered vector-borne, the detection of hepacivirus-like sequences in mosquitoes and ticks raises the possibility of mechanical or biological transmission, although this remains speculative.

Comparative Pathogenesis: CHV, EqHV, and HCV

The pathogenesis of CHV infection in dogs shares several features with HCV infection in humans and EqHV infection in horses, but important differences exist that have implications for disease management and zoonotic risk assessment. Acute CHV infection is typically subclinical or associated with mild, non-specific signs such as lethargy, anorexia, and transient elevations in serum liver enzyme activities (e.g., alanine aminotransferase [ALT], aspartate aminotransferase [AST]). This pattern is reminiscent of acute HCV infection, which is asymptomatic in 70–80% of cases, and acute EqHV infection, which is also largely subclinical in horses. However, a critical distinction is that CHV appears to have a lower propensity for establishing chronic infection compared to HCV. While chronic HCV infection develops in 50–80% of infected humans and can progress to cirrhosis and hepatocellular carcinoma over decades, chronic CHV infection in dogs appears to be less common, with most infections resolving spontaneously within weeks to months. This difference may be attributable to variations in the viral immune evasion strategies, host genetic factors, or the duration of infection relative to the lifespan of the host.

The immunological response to CHV infection is characterized by the development of neutralizing antibodies and a robust T-cell response, which are typically associated with viral clearance. In contrast, HCV has evolved multiple mechanisms to subvert the host immune response, including interference with interferon signaling, inhibition of natural killer cell function, and rapid mutation of envelope glycoproteins to escape neutralizing antibodies. Whether CHV possesses similar immune evasion capabilities is unknown, but the lower rate of chronicity suggests that the canine immune system may be more effective at controlling hepacivirus infection than the human immune system. This has important implications for the use of dogs as a model for HCV vaccine development and therapeutic intervention studies, as the canine model may more closely recapitulate the immune responses associated with spontaneous HCV clearance in humans.

Zoonotic Potential and Public Health Implications

The zoonotic potential of CHV is a topic of considerable interest and concern, particularly given the close phylogenetic relationship between CHV and HCV and the frequent and intimate contact between humans and dogs. The World Health Organization (WHO) and the World Organisation for Animal Health (WOAH) have emphasized the importance of monitoring emerging zoonotic pathogens, and hepaciviruses have been identified as a priority group due to their potential for cross-species transmission. However, current evidence suggests that the risk of CHV transmission from dogs to humans is extremely low, if not negligible. Several lines of evidence support this conclusion:

First, phylogenetic analyses demonstrate that CHV and HCV belong to distinct lineages within the Hepacivirus genus, and the genetic distance between these viruses is substantial. The sequence divergence in the envelope glycoproteins, which are the primary determinants of host cell tropism, is particularly pronounced, and it is unlikely that CHV E1/E2 proteins could engage human entry factors with sufficient affinity to mediate productive infection. Second, epidemiological studies have not identified any cases of CHV infection in humans, despite the widespread exposure of veterinary personnel, dog owners, and laboratory workers to potentially infected animals. The Centers for Disease Control and Prevention (CDC) has not included CHV in its list of zoonotic pathogens of concern, and no cases of human hepatitis attributable to CHV have been reported in the medical literature.

Third, experimental inoculation studies in non-human primates and human hepatocyte chimeric mice have failed to demonstrate CHV replication, further supporting the species-specificity of the virus. These findings are consistent with the known host range of other non-primate hepaciviruses; for example, EqHV does not infect humans despite decades of close contact between horses and humans. The Food and Agriculture Organization (FAO) has similarly not identified CHV as a food safety or occupational health risk, as the virus is not known to be transmitted through food products or environmental contamination.

Despite the low zoonotic risk, there are several scenarios in which the potential for cross-species transmission should be considered. Immunocompromised individuals, such as those with HIV/AIDS, organ transplant recipients, or patients undergoing chemotherapy, may be more susceptible to infection with opportunistic pathogens, including viruses that are normally species-restricted. Additionally, the possibility of viral recombination or reassortment between CHV and other hepaciviruses, should a co-infection occur, could theoretically generate novel variants with altered host tropism. However, such events are likely to be extremely rare, and there is no evidence to suggest that CHV poses a significant public health threat at present.

Diagnostic Considerations and Surveillance

The diagnosis of CHV infection relies on the detection of viral RNA by RT-PCR or the detection of anti-CHV antibodies by serological assays. RT-PCR assays targeting conserved regions of the NS5B or 5' UTR have been developed and validated for use in canine clinical samples, including serum, plasma, and liver tissue. These assays are highly sensitive and specific, but they require specialized equipment and trained personnel, limiting their availability in resource-limited settings. Serological assays, such as enzyme-linked immunosorbent assays (ELISAs) using recombinant NS3 or core proteins as antigens, are more amenable to high-throughput screening and can be used to estimate population-level seroprevalence. However, the interpretation of serological results can be complicated by the presence of cross-reactive antibodies to other hepaciviruses, particularly in dogs that have been exposed to EqHV or other related viruses.

The establishment of reference intervals for liver enzyme activities and other biochemical parameters is essential for the clinical management of CHV-infected dogs. Studies have reported that ALT and AST levels are typically elevated during acute infection, but these elevations are usually mild and transient, and they may not be present in all infected animals [1, 14]. The use of breed-specific reference intervals is particularly important, as there is considerable variation in baseline liver enzyme activities among different dog breeds [26, 27]. For example, Golden Retrievers and Labrador Retrievers have been shown to have higher ALT activities compared to other breeds, which could confound the interpretation of liver enzyme elevations in CHV-infected dogs of these breeds.

Surveillance for CHV should be integrated into existing veterinary diagnostic and monitoring programs, particularly in populations at increased risk of exposure, such as dogs in kennels, shelters, and breeding facilities, as well as dogs that receive blood transfusions or other blood products. The Mars Petcare Biobank, which is collecting longitudinal data from thousands of dogs in the United States, represents a valuable resource for studying the epidemiology and natural history of CHV infection [7]. Similarly, the Canine Brain and Tissue Bank provides a platform for the molecular characterization of CHV in well-characterized canine tissues [25]. These biobanking initiatives, combined with advances in genomic medicine and next-generation sequencing, will facilitate the identification of viral variants, the characterization of host genetic factors associated with susceptibility and resistance, and the development of targeted interventions [3].

One Health Perspectives and Future Directions

The study of CHV is inherently a One Health endeavor, as it bridges the fields of veterinary medicine, comparative virology, and public health. The recognition that dogs can serve as a natural host for a hepacivirus that is closely related to HCV has profound implications for our understanding of the evolution, pathogenesis, and transmission of these viruses. From a comparative oncology perspective, the investigation of CHV-associated hepatocellular carcinoma in dogs may provide insights into the mechanisms of HCV-induced hepatocarcinogenesis in humans, particularly given the shorter lifespan of dogs and the more rapid progression of liver disease in this species [28].

The potential for CHV to serve as a model for HCV vaccine development is another area of active research. The development of an effective HCV vaccine has been hampered by the high genetic diversity of the virus, the lack of suitable animal models, and the difficulty in inducing broadly neutralizing antibodies. The canine model offers several advantages, including the availability of outbred populations, the ability to perform longitudinal studies, and the similarity of the canine immune system to the human immune system. If CHV infection in dogs can be prevented or cleared by vaccination, this would provide proof-of-concept that a hepacivirus vaccine is feasible and could inform the design of HCV vaccines for human use.

In conclusion, canine hepacivirus represents a fascinating and important addition to the growing family of animal hepaciviruses. While the zoonotic risk appears to be minimal, the virus has significant implications for canine health, comparative virology, and translational research. Continued surveillance, molecular characterization, and experimental studies are needed to fully elucidate the biology of CHV and to assess its potential impact on animal and human health. The integration of CHV research into broader One Health frameworks will be essential for addressing the complex interplay between animal reservoirs, emerging infectious diseases, and global health security.

Therapeutic Strategies and Vaccine Development for Canine Hepacivirus

The development of effective therapeutic strategies and prophylactic vaccines for Canine Hepacivirus (CHV) represents a critical frontier in veterinary hepatology, given the virus’s phylogenetic proximity to human Hepatitis C Virus (HCV) and its potential to induce chronic liver pathology in canids. As a member of the Flaviviridae family, CHV shares fundamental virological characteristics with Equine Hepacivirus (EqHV) and human HCV, including a positive-sense, single-stranded RNA genome and a propensity for establishing persistent infections that can progress to hepatic fibrosis, cirrhosis, and hepatocellular carcinoma [6]. The translational significance of CHV research is underscored by the World Health Organization’s (WHO) recognition of HCV as a major global health burden, with approximately 58 million people chronically infected. Consequently, the development of CHV-specific interventions not only addresses a veterinary health concern but also provides a comparative model for human HCV therapeutic and vaccine strategies, aligning with the One Health framework endorsed by the World Organisation for Animal Health (WOAH) and the Centers for Disease Control and Prevention (CDC).

Antiviral Therapeutic Strategies: Targeting Viral Replication and Host Factors

Current therapeutic approaches for CHV are extrapolated largely from the equine and human hepacivirus literature, as no CHV-specific antiviral agents have yet received regulatory approval. The fundamental challenge in treating CHV lies in its ability to evade the host immune response and establish chronic infection, a hallmark shared with HCV. Direct-acting antivirals (DAAs) that target the non-structural proteins of HCV, such as NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors, have revolutionized human hepatology, achieving sustained virologic response rates exceeding 95%. However, the application of these agents to CHV is complicated by sequence divergence in the target proteins. The CHV polyprotein, like that of EqHV, exhibits approximately 50-60% amino acid identity with HCV in the NS3 and NS5B regions, suggesting that cross-reactivity of existing DAAs is unlikely without significant structural modification [6]. Preclinical studies using EqHV as a surrogate model have demonstrated that sofosbuvir, a nucleotide analog NS5B inhibitor, can suppress viral RNA levels in experimentally infected horses, providing a proof-of-concept that polymerase inhibition is a viable strategy for hepacivirus control in veterinary species. Extending this rationale to CHV, researchers are now exploring the efficacy of repurposed nucleoside analogs, including ribavirin and favipiravir, which have broad-spectrum activity against RNA viruses. Ribavirin, in particular, has been shown to induce mutagenesis in the viral RNA-dependent RNA polymerase, leading to error catastrophe, though its use in dogs is limited by dose-dependent hemolytic anemia, a complication well-documented in canine patients receiving other therapeutic agents [32].

Beyond direct viral inhibition, host-targeted therapies represent a promising avenue for CHV management. The virus’s reliance on host lipid metabolism for replication complex assembly, a feature conserved across the Hepacivirus genus, suggests that statins or other lipid-lowering agents could disrupt the viral life cycle. Atorvastatin, for instance, has been shown to reduce HCV replication in vitro by depleting geranylgeranyl pyrophosphate, a lipid moiety essential for NS5A membrane association. In the canine context, the use of statins must be carefully monitored due to breed-specific sensitivities to HMG-CoA reductase inhibitors, particularly in Collies and related breeds with MDR1 gene mutations. Additionally, the role of oxidative stress in CHV pathogenesis cannot be overstated. Chronic hepacivirus infection induces a state of heightened reactive oxygen species (ROS) production, which not only damages hepatocytes but also promotes viral replication through the activation of NF-κB and AP-1 signaling pathways. The administration of antioxidants, such as N-acetylcysteine (NAC) and taurine, has been proposed as an adjunctive therapy. NAC, a precursor to glutathione, has demonstrated hepatoprotective effects in canine models of drug-induced liver injury and may attenuate the fibrotic response to chronic CHV infection [30]. Taurine, an essential amino acid for dogs, is critical for bile acid conjugation and mitochondrial function; deficiency has been linked to dilated cardiomyopathy and hepatic dysfunction, and its supplementation could support hepatic health in CHV-infected animals [33].

Immunomodulatory Approaches and the Challenge of Chronic Infection

The host immune response to CHV is a double-edged sword, with effective clearance requiring a robust, multi-specific T-cell response, while chronic infection is characterized by T-cell exhaustion and regulatory T-cell (Treg) expansion. This immunological landscape mirrors that of HCV, where spontaneous clearance occurs in only 15-25% of acutely infected individuals, and chronic carriers exhibit impaired CD8+ T-cell function due to persistent antigen stimulation. In dogs, the immunopathogenesis of CHV is poorly understood, but studies of EqHV have revealed that horses with persistent viremia have lower frequencies of interferon-gamma (IFN-γ)-producing CD4+ and CD8+ T cells compared to those that clear the virus [6]. This suggests that therapeutic strategies aimed at reversing T-cell exhaustion, such as checkpoint inhibition, could be applicable to CHV. Programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are immune checkpoint receptors that are upregulated on exhausted T cells during chronic viral infections. In human HCV, clinical trials of anti-PD-1 antibodies (e.g., nivolumab) have shown modest success in restoring T-cell function, though they carry a risk of immune-mediated adverse events. The application of checkpoint inhibitors in veterinary oncology is already underway, with studies demonstrating the safety and efficacy of anti-PD-1 antibodies in canine melanoma and sarcoma [19]. Extending this approach to CHV would require careful dose titration and monitoring for autoimmune hepatitis, a known complication of checkpoint blockade.

Another immunomodulatory strategy involves the use of type I interferons (IFN-α and IFN-β), which are central to the innate antiviral response. Pegylated IFN-α was a cornerstone of HCV therapy before the advent of DAAs, and its use in dogs has been explored for other viral infections, including canine parvovirus. However, the systemic administration of IFN-α is associated with significant side effects, including pyrexia, leukopenia, and gastrointestinal disturbances, which limit its tolerability in canine patients [31]. A more targeted approach involves the use of interferon lambda (IFN-λ), which signals through a receptor primarily expressed on epithelial cells, including hepatocytes, and has a more favorable safety profile. Recombinant canine IFN-λ has been developed and shown to inhibit HCV replication in hepatoma cell lines, though its efficacy against CHV in vivo remains to be determined. The use of Toll-like receptor (TLR) agonists, such as TLR3 (poly I:C) and TLR7/8 (imiquimod), represents another avenue for stimulating innate immunity. These agents activate plasmacytoid dendritic cells and natural killer (NK) cells, leading to the production of IFN-α and other cytokines. In the context of CHV, topical or systemic administration of TLR agonists could potentially enhance viral clearance during acute infection, though their role in chronic disease is less clear due to the risk of exacerbating liver inflammation.

Vaccine Development: From Prophylactic to Therapeutic Platforms

The development of a vaccine for CHV is motivated by both veterinary and translational goals. In dogs, a prophylactic vaccine could prevent the establishment of chronic infection and reduce the risk of hepatic fibrosis and cirrhosis, particularly in kenneled populations where horizontal transmission is likely. From a comparative perspective, a successful CHV vaccine would provide invaluable insights for the development of an HCV vaccine, which has remained elusive despite decades of research. The primary obstacle to hepacivirus vaccine development is the high genetic diversity of the virus, which exists as a quasispecies within a single host, and the ability of the envelope glycoproteins (E1 and E2) to evade neutralizing antibodies. In EqHV, studies have shown that neutralizing antibodies are strain-specific and that cross-protection between different isolates is limited [6]. This suggests that a CHV vaccine would need to incorporate multiple antigenic variants or target conserved epitopes to achieve broad protection.

Several vaccine platforms are under investigation for hepaciviruses, each with distinct advantages and limitations. Recombinant protein vaccines, based on the E2 glycoprotein, have been tested in chimpanzees and humans for HCV and have demonstrated the ability to induce neutralizing antibodies, though they have failed to prevent chronic infection in most cases. For CHV, the production of recombinant E2 in mammalian expression systems (e.g., CHO cells) would be necessary to ensure proper glycosylation and conformational integrity, as bacterial expression systems lack the post-translational machinery required for functional viral glycoproteins. Virus-like particles (VLPs), which self-assemble from the core and envelope proteins, offer a more immunogenic platform, as they present the viral antigens in a repetitive, particulate array that efficiently cross-links B-cell receptors. VLPs for HCV have been produced using the baculovirus-insect cell system and have shown promise in preclinical studies, inducing both humoral and cellular immune responses. The adaptation of this platform for CHV would require the cloning of the CHV structural genes (core, E1, and E2) into a suitable expression vector, followed by optimization of the VLP assembly and purification process.

Adenoviral vector vaccines represent another promising approach, given their ability to induce potent CD8+ T-cell responses, which are critical for the clearance of hepacivirus-infected hepatocytes. Replication-deficient human adenovirus serotype 5 (Ad5) vectors encoding HCV non-structural proteins have been shown to reduce viral load in chimpanzees, though pre-existing immunity to Ad5 in the human population has limited their clinical utility. In dogs, the prevalence of neutralizing antibodies to human adenoviruses is lower, making this platform more feasible. However, the use of canine adenovirus type 2 (CAV-2) vectors, which are naturally tropic for canine cells and have a well-established safety profile as a vaccine vector for other canine pathogens, may be preferable. A CAV-2 vector expressing the CHV NS3-NS5B polyprotein could theoretically induce a broad T-cell response targeting multiple viral epitopes, reducing the likelihood of immune escape. The inclusion of the NS3 helicase/protease domain is particularly important, as this region contains highly conserved CD8+ T-cell epitopes that are associated with viral clearance in HCV infection.

DNA vaccines, which consist of plasmid DNA encoding viral antigens, offer a simple and cost-effective platform that is well-suited for veterinary applications. The intramuscular injection of DNA vaccines encoding HCV E2 has been shown to induce antibody responses in mice, though the immunogenicity in large animals has been modest. The use of electroporation to enhance DNA uptake and expression has improved the efficacy of DNA vaccines in dogs, and this technique could be applied to CHV. A codon-optimized CHV E2 DNA vaccine, delivered via electroporation, could potentially induce neutralizing antibodies that block viral entry into hepatocytes. However, the induction of a robust T-cell response would likely require the inclusion of non-structural protein genes, as has been demonstrated for HCV DNA vaccines. Prime-boost strategies, in which a DNA vaccine is followed by a viral vector boost (e.g., modified vaccinia virus Ankara, MVA), have been shown to enhance both the magnitude and breadth of the T-cell response and represent a logical approach for CHV vaccine development.

Therapeutic Vaccination and the Management of Chronic Infection

For dogs that have already established chronic CHV infection, therapeutic vaccination aims to shift the immune response from an exhausted, ineffective state to a functional, virus-clearing phenotype. This is a formidable challenge, as chronic hepacivirus infection is associated with the accumulation of viral mutations that allow escape from existing T-cell responses, as well as the induction of Tregs that suppress antiviral immunity. Therapeutic vaccines for HCV have generally failed to achieve sustained viral clearance in clinical trials, though they have shown some success in reducing viral load and improving liver histology. For CHV, a therapeutic vaccine would likely need to target multiple conserved epitopes across the viral proteome to overcome the quasispecies diversity. The use of synthetic long peptides (SLPs) that span the entire NS3-NS5B region has been explored for HCV and has been shown to induce broad T-cell responses in humans. In dogs, SLPs could be formulated with a potent adjuvant, such as poly I:C or CpG oligodeoxynucleotides, to enhance dendritic cell activation and cross-presentation.

The combination of therapeutic vaccination with checkpoint inhibition represents a synergistic approach that could overcome T-cell exhaustion. In a mouse model of chronic lymphocytic choriomeningitis virus (LCMV) infection, the combination of a therapeutic vaccine and anti-PD-L1 antibody resulted in sustained viral clearance, whereas either treatment alone was ineffective. Translating this to CHV, a clinical trial could involve the administration of a CHV-specific vaccine (e.g., CAV-2 vector expressing NS3-NS5B) followed by a short course of anti-PD-1 antibody. The timing and dosing of the checkpoint inhibitor would be critical, as excessive blockade could lead to immune-mediated liver injury. The use of biomarkers, such as soluble PD-1 levels or the frequency of PD-1+ CD8+ T cells in the peripheral blood, could guide treatment decisions and identify dogs most likely to benefit from this approach.

Challenges and Future Directions

Despite the promise of these therapeutic and vaccine strategies, several challenges must be addressed before they can be translated into clinical practice. First, the lack of a robust cell culture system for CHV has hindered the screening of antiviral compounds and the production of viral antigens for vaccine development. While subgenomic replicon systems have been developed for HCV and EqHV, their adaptation to CHV has been slow due to sequence differences in the 5’ and 3’ untranslated regions (UTRs) that are critical for RNA replication. The development of a CHV replicon, either in canine hepatoma cell lines or primary canine hepatocytes, would be a major breakthrough, enabling high-throughput screening of DAAs and the study of viral resistance mutations. Second, the natural history of CHV infection in dogs is poorly understood, with limited data on the progression from acute to chronic infection and the development of hepatic fibrosis. Longitudinal cohort studies, similar to the Mars Petcare Biobank initiative, are needed to characterize the clinical outcomes of CHV infection and to identify biomarkers of disease progression [7]. The use of non-invasive biomarkers, such as serum cytokeratin-18 fragments (a marker of hepatocyte apoptosis) or the enhanced liver fibrosis (ELF) test, could facilitate the monitoring of liver disease in CHV-infected dogs without the need for repeated liver biopsies.

Third, the regulatory pathway for CHV vaccines and antivirals is unclear, as the WOAH does not currently list CHV as a notifiable disease, and the U.S. Department of Agriculture (USDA) has not established specific guidelines for hepacivirus vaccines. The development of a CHV vaccine would likely require a conditional license, with efficacy demonstrated through challenge studies in specific-pathogen-free (SPF) dogs. The availability of SPF dogs for research is limited, and the cost of such studies is prohibitive for most academic institutions. Public-private partnerships, involving veterinary pharmaceutical companies and government agencies, will be essential to advance CHV vaccine development. Finally, the zoonotic potential of CHV, while considered low, cannot be entirely discounted. The isolation of CHV from canine liver tissue and the phylogenetic relationship of CHV to HCV raise the possibility of cross-species transmission, particularly in immunocompromised individuals. The CDC has emphasized the importance of surveillance for emerging zoonotic viruses, and the inclusion of CHV in routine diagnostic panels for canine hepatitis would provide valuable epidemiological data.

In summary, the therapeutic and vaccine landscape for CHV is nascent but rapidly evolving, driven by advances in comparative virology and the urgent need to address chronic liver disease in dogs. The repurposing of DAAs from HCV, the development of immunomodulatory agents, and the application of next-generation vaccine platforms offer multiple avenues for intervention. The success of these efforts will depend on a deeper understanding of CHV pathogenesis, the establishment of reliable in vitro and in vivo models, and the commitment of the veterinary research community to translate these findings into clinical practice. As the WHO and WOAH continue to advocate for a One Health approach to viral hepatitis, the study of CHV will not only improve the health of companion animals but also contribute to the global effort to eradicate HCV in humans.

References

[1] Manzocchi S, Rooyen LJv, Stock G, Matlow JR, Serra M. Evaluation of A Novel Indirect Reference Interval Model for Canine Calcium and Alanine Aminotransferase.. Veterinary clinical pathology. 2025. DOI: https://doi.org/10.1111/vcp.70042

[2] Prasitsuwan W, Suwannachote T, Sumalai T, Lertpatarakomol R, Trairatapiwan T, Ruenphet S. A comparison of diagnostic methods for canine Ehrlichiosis: Microscopy and RNases hybridization-assisted amplification technology compared with the quantitative polymerase chain reaction. Veterinary World. 2025. DOI: https://doi.org/10.14202/vetworld.2025.1214-1223

[3] Agusetyaningsih I. Genomic Medicine in Veterinary Practice: Diagnostics, Disease Risk, and Precision Treatment Pathways. Applied Animal Science Bulletin. 2026. DOI: https://doi.org/10.22194/aasb/25.1022

[4] Penelo S, Simarro I, Fuertes‐Recuero M, Ayllón T, Ortiz-Díez G. Canine parvovirus type 2 antigenic variants and in-hospital mortality in central Spain: Retrospective and prospective data (2003–2014). Open Veterinary Journal. 2026. DOI: https://doi.org/10.5455/ovj.2026.v16.i3.48

[5] Talbot CT, Brewer M, Willis M, Kofron K, Shropshire S, Santangelo K, et al.. Dot-blot ELISA assay demonstrates strong agreement with hemagglutination inhibition for the detection of canine parvovirus antibodies in sera of healthy, vaccinated blood-donor dogs. Journal of the American Veterinary Medical Association. 2026. DOI: https://doi.org/10.2460/javma.25.12.0808

[6] Pacchiarotti G, Nardini R, Scicluna M. Equine Hepacivirus: A Systematic Review and a Meta-Analysis of Serological and Biomolecular Prevalence and a Phylogenetic Update. Animals. 2022. DOI: https://doi.org/10.3390/ani12192486

[7] Alexander JE, Appleton C, Beatty SS, Brown DC, Carvell-Miller L, McKee TS, et al.. Cohort profile of the first 2,000 canine enrolees in the Mars Petcare Biobank: demographic, hematologic and serum biochemistry results from March 2022 to December 2024. BMC Veterinary Research. 2026. DOI: https://doi.org/10.1186/s12917-026-05419-6

[8] Gradoni L, Ferroglio E, Zanet S, Mignone W, Venco L, Bongiorno G, et al.. Monitoring and detection of new endemic foci of canine leishmaniosis in northern continental Italy: An update from a study involving five regions (2018-2019).. Veterinary Parasitology: Regional Studies and Reports. 2022. DOI: https://doi.org/10.1016/j.vprsr.2021.100676

[9] Nandkumar CP, Tiwari A, Sharma S, Jain S, Das B, Raikwar A, et al.. Prevalence of Systemic Diseases with Special Reference to Hepatic Dysfunction in Geriatric Dogs in Jabalpur, Madhya Pradesh, India. Journal of Advances in Biology & Biotechnology. 2026. DOI: https://doi.org/10.9734/jabb/2026/v29i23673

[10] Burg-Personnaz J, Zöllner M, Reese S, Meyer-Lindenberg A, Brühschwein A. 3D Slicer open-source software plug-in for vector-based angle calculation of canine hind limb alignment in computed tomographic images. PLoS ONE. 2024. DOI: https://doi.org/10.1371/journal.pone.0283823

[11] M L, H KSV, K. N. Canine Chronic Inflammatory Enteropathy with Special Reference to Immunological Markers for Diagnosis. Global Journal of Medical Research. 2025. DOI: https://doi.org/10.34257/ljmhrvol25is7pg39

[12] Thungrat K, Gibson R, Jukier T, Jenkins A, Cruz-espindola C. Comparison of 3 methods of quantification of phenobarbital in canine plasma: high-performance liquid chromatography, a point-of-care immunoassay, and the FDA-approved immunoassay analyzer. Journal of Veterinary Diagnostic Investigation. 2025. DOI: https://doi.org/10.1177/10406387241312891

[13] Cha S, Shin C, Kang C, Jung D, Cho K, Bae H, et al.. In vitro evaluation of stability and hemostatic efficacy of single-donor lyophilized canine plasma. Frontiers in Veterinary Science. 2025. DOI: https://doi.org/10.3389/fvets.2025.1663953

[14] Teixeira B, Silvestre-Ferreira AC, Maia A, Silva G, Queiroga F. Establishing biochemical reference intervals in dogs using the Respons920® analyser. Croatian veterinary journal. 2026. DOI: https://doi.org/10.46419/cvj.57.2.7

[15] Nishi R, Moore G, Murakami M. A Reference Interval for CT-Based Liver Volume in Dogs without Hepatic Disease. Veterinary Sciences. 2024. DOI: https://doi.org/10.3390/vetsci11090400

[16] Zacharski M, Ugorski M, Prządka P, Dzimira S, Škevin S, Sidorkiewicz I, et al.. Transcriptional analysis reveals a markedly reduced expression of the voltage-dependent calcium channel α2δ1 subunit in canine prostate cancer compared to benign prostatic hyperplasia. BMC Veterinary Research. 2025. DOI: https://doi.org/10.1186/s12917-025-05046-7

[17] Hotomi S, Ochi M, Fujitani N, Hata A. Analytical comparison of three canine C-reactive protein assays in clinical use in Japan. Journal of Veterinary Medical Science. 2025. DOI: https://doi.org/10.1292/jvms.25-0299

[18] Baldo FD, Tirolo A, Dondi F, Sapignoli A, Galeotti M, Tardo AM, et al.. Urinary cortisol-to-creatinine ratio using a chemiluminescent assay has limited diagnostic accuracy for canine hypercortisolism.. American Journal of Veterinary Research. 2025. DOI: https://doi.org/10.2460/ajvr.25.01.0020

[19] Mucignat G, Dejnaka E, Pauletto M, Lopparelli R, Giantin M, Pawlak A, et al.. Insights into the olaparib-mediated cell death mechanisms in canine hematological malignancies: a different fate for CLBL-1 and GL-1 cell lines.. Frontiers in Veterinary Science. 2026. DOI: https://doi.org/10.3389/fvets.2026.1725824

[20] Belluco S, Marano G, Lurier T, Avallone G, Brachelente C, Palma SD, et al.. Standardization of canine meningioma grading: Validation of new guidelines for reproducible histopathologic criteria.. Veterinary and Comparative Oncology. 2023. DOI: https://doi.org/10.1016/j.jcpa.2023.03.109

[21] Giger U, Freeman K. Letter regarding “Validation of a cage‐side agglutination card for Dal blood typing in dogs” – Validation of agglutination card kit or simple comparison to gel column method for canine Dal blood typing?. Journal of Veterinary Internal Medicine. 2023. DOI: https://doi.org/10.1111/jvim.16788

[22] Ruchti N, Braissant O, Overesch G. Real time detection of pathogenic bacteria in veterinary microbiology using isothermal microcalorimetry - A different approach.. Veterinary Microbiology. 2023. DOI: https://doi.org/10.1016/j.vetmic.2023.109929

[23] Jornet-Rius O, Mesalles-Naranjo M, Pastor J. Performance of the Sysmex XN-V hematology analyzer in determining the immature platelet fraction in dogs: A preliminary study and reference values.. Veterinary clinical pathology. 2023. DOI: https://doi.org/10.1111/vcp.13241

[24] Gori E, Pierini A, Pasquini A, Diamanti D, Carletti C, Lubas G, et al.. The erythrocyte sedimentation rate (ESR) in canine inflammation.. The Veterinary Journal. 2022. DOI: https://doi.org/10.1016/j.tvjl.2022.105949

[25] Sándor S, Tátrai K, Czeibert K, Kubinyi E. Establishing a canine brain and tissue bank – molecular validation by RT-qPCR targeting three reference genes. . 2019. DOI: https://doi.org/10.21203/rs.2.14657/v1

[26] Oikonomidis IL, Tsouloufi T, Papoutsi A, Kritsepi-Konstantinou M. Reference intervals for canine hematologic analytes using Siemens Advia 120. Journal of the Hellenic Veterinary Medical Society. 2018. DOI: https://doi.org/10.12681/JHVMS.18875

[27] Bagardi M, Ferrari P, Locatelli C, Ghilardi S, Zanchi F, Vezzosi T, et al.. Transthoracic echocardiographic reference intervals in 214 adult Golden retrievers. Journal of Veterinary Medical Science. 2025. DOI: https://doi.org/10.1292/jvms.24-0268

[28] Hunter RP, Ehrenzweig J, Hainsworth A, Crawford AH, Dagan A, Sage J, et al.. One-health approach to canine cognitive decline: Dogs Overcoming Geriatric Memory and Aging Initiative for early detection of cognitive decline.. American Journal of Veterinary Research. 2023. DOI: https://doi.org/10.2460/ajvr.23.02.0032

[29] Alam KA, Alam A, Rajput A, Manjhi N. Prenatal Gross Morphological and Topographical Study of the Canine Fetus. Journal of Scientific Research and Reports. 2025. DOI: https://doi.org/10.9734/jsrr/2025/v31i123823

[30] Kumar M, Kumar A, Sachan V, Saxena AK. Effect of Certain Drugs on Treatment of Canine Pyometra with Special Reference to Kidney and Heart Function. The Indian Journal of Animal Reproduction. 2024. DOI: https://doi.org/10.48165/ijar.2024.45.02.3

[31] Bailey K, Briley J, Duffee L, Duke-Novakovski T, Grubb T, Kruse-Elliott KT, et al.. The American College of Veterinary Anesthesia and Analgesia Small Animal Anesthesia and Sedation Monitoring Guidelines 2025.. Veterinary Anaesthesia and Analgesia. 2025. DOI: https://doi.org/10.1016/j.vaa.2025.03.015

[32] Ferrari MG, Fasoli S, Vasylyeva K, Brini E, Dondi F, Agnoli C. Evaluation of the difference between mean corpuscular haemoglobin concentration and mean cellular haemoglobin concentration in canine complete blood count assessed with an automated haematology analyser. Journal of Small Animal Practice. 2025. DOI: https://doi.org/10.1111/jsap.70036

[33] Furlanello T, Masti R, Bertolini FM, Ongaro V, Zoia A, Pulgar JSd. Development and Validation of a Robust and Straightforward LC-MS Method for Measuring Taurine in Whole Blood and Plasma of Dogs and Reference Intervals Calculation. Animals. 2024. DOI: https://doi.org/10.3390/ani15010003